In a groundbreaking development that offers new hope to millions, a stem cell therapy developed by Vertex Pharmaceuticals has shown the potential to act as a “functional cure” for Type 1 diabetes. Early results from a clinical trial revealed that patients receiving the treatment, called VX-880, were able to live without daily insulin injections for over a year.

Type 1 diabetes is an autoimmune disease where the body’s immune system mistakenly attacks and destroys the insulin-producing islet cells in the pancreas. Without insulin, the body cannot properly regulate blood sugar, forcing patients to rely on a lifetime of insulin shots and constant monitoring.

Vertex’s innovative therapy aims to reverse this. Scientists use stem cells to grow brand-new, healthy islet cells in a lab. These new cells are then infused into the patient, where they begin to produce insulin on their own, effectively replacing the ones that were destroyed.

The results, presented at the American Diabetes Association’s annual conference, were remarkable. Two patients who completed the therapy have now been insulin-independent for one and two years, respectively. Their bodies are now able to naturally control their blood sugar levels, even after eating. All 12 patients in the study showed significant improvements, producing their own insulin and drastically reducing their need for shots.

However, the current therapy has one major hurdle: patients must take immunosuppressant drugs to prevent their bodies from rejecting the newly infused cells. These drugs come with their own set of health risks and side effects.

Recognizing this challenge, Vertex is already developing a next-generation version of the treatment. This new approach involves encapsulating the stem cells in a protective device before infusion, which could shield them from the immune system and eliminate the need for immunosuppressant drugs. This advanced therapy is currently in the early stages of clinical trials.

While still in development, the success of VX-880 marks a monumental step forward in treating Type 1 diabetes, moving from daily management to a potential one-time, curative treatment.

Read More: Peace in Our Time? Trump Touts Diplomatic Wins, But History Tells a More Complicated Story